Cost-effectiveness analysis of intradermal versus classical intramuscular COVID-19 vaccine administration

Authors

DOI:

https://doi.org/10.3329/bjp.v17i1.57593

Keywords:

Cost-effectiveness, COVID-19 , Vaccine

Abstract

n/a

Downloads

Download data is not yet available.
Abstract
100
Download
67

Author Biographies

Pathum Sookaromdee, Private Academic Consultant Center, Bangkok, Thailand.

Private Consultant

Viroj Wiwanitkit, Department of Community Medicine, Dr. D. Y. Patil University, Pune, India.

Honorary Professor

References

Hsia W. Emerging new coronavirus infection in Wuhan, China: Situation in early 2020. Case Study Case Rep. 2020; 10: 8-9.

Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, Sawaengdee W, Phumiamorn S, Sapsutthipas S, Sangsupawanich P, Chusri S, Pinpathomrat N. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population. Vaccines (Basel) 2021. 9: 1375.

Karim SA. COVID‑19 vaccine affordability and accessibility. Lancet 2020; 396: 238.

Schnyder JL, de Jong HK, Grobusch MP. Intradermal immunization: A dose-sparing strategy to combat global shortages of severe acute respiratory syndrome coronavirus 2 vaccines? Clin Microbiol Infect. 2022; 28: 6-8.

Schweiger M. Intradermal covid-19 vaccination could solve supply problems. BMJ. 2021; 374: 1980.

Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. The COVID-19 vaccine race: Challenges and opportunities in vaccine formulation. AAPS Pharm Sci Tech. 2020; 21: 225.

Downloads

Published

2022-03-17

How to Cite

Sookaromdee, P., and V. . Wiwanitkit. “Cost-Effectiveness Analysis of Intradermal Versus Classical Intramuscular COVID-19 Vaccine Administration”. Bangladesh Journal of Pharmacology, vol. 17, no. 1, Mar. 2022, pp. 9-10, doi:10.3329/bjp.v17i1.57593.

Issue

Section

Letter to the Editor